US8440221B2 - Transdermal drug delivery method and system - Google Patents
Transdermal drug delivery method and system Download PDFInfo
- Publication number
- US8440221B2 US8440221B2 US10/711,389 US71138904A US8440221B2 US 8440221 B2 US8440221 B2 US 8440221B2 US 71138904 A US71138904 A US 71138904A US 8440221 B2 US8440221 B2 US 8440221B2
- Authority
- US
- United States
- Prior art keywords
- active substance
- administration
- reservoir
- solvent
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 238000000034 method Methods 0.000 title description 15
- 238000013271 transdermal drug delivery Methods 0.000 title description 14
- 239000013543 active substance Substances 0.000 claims abstract description 129
- 239000002904 solvent Substances 0.000 claims abstract description 125
- 238000012384 transportation and delivery Methods 0.000 claims description 47
- 239000000126 substance Substances 0.000 claims description 28
- 239000012528 membrane Substances 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 20
- 238000010521 absorption reaction Methods 0.000 claims description 15
- 238000001704 evaporation Methods 0.000 claims description 14
- 230000008020 evaporation Effects 0.000 claims description 14
- 230000002745 absorbent Effects 0.000 claims description 13
- 239000002250 absorbent Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 239000002274 desiccant Substances 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- 239000003380 propellant Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002808 molecular sieve Substances 0.000 claims description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 abstract description 34
- 238000009792 diffusion process Methods 0.000 abstract description 25
- 239000012530 fluid Substances 0.000 abstract description 18
- 230000037317 transdermal delivery Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 description 106
- 229940079593 drug Drugs 0.000 description 97
- 210000003491 skin Anatomy 0.000 description 79
- 238000012377 drug delivery Methods 0.000 description 17
- 239000010410 layer Substances 0.000 description 17
- 239000002699 waste material Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000003623 enhancer Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000035699 permeability Effects 0.000 description 6
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000012790 adhesive layer Substances 0.000 description 5
- 239000012867 bioactive agent Substances 0.000 description 5
- 229960002715 nicotine Drugs 0.000 description 5
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 239000013557 residual solvent Substances 0.000 description 5
- 239000013583 drug formulation Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- -1 nitroglycerine Chemical compound 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229920000544 Gore-Tex Polymers 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000027288 circadian rhythm Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- KRUABTDBQQLWLS-UHFFFAOYSA-N 1-methylsulfinyltetradecane Chemical compound CCCCCCCCCCCCCCS(C)=O KRUABTDBQQLWLS-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 239000004821 Contact adhesive Substances 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011796 hollow space material Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229940035321 transderm scop Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Abstract
Description
Claims (25)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/892,006 US8673346B2 (en) | 2003-10-27 | 2013-05-10 | Transdermal drug delivery method and system |
US14/162,156 US20140200525A1 (en) | 2003-10-27 | 2014-01-23 | Biosynchronous transdermal drug delivery |
US14/746,689 US9555226B2 (en) | 2003-10-27 | 2015-06-22 | Transdermal drug delivery method and system |
US15/385,638 US10716764B2 (en) | 2003-10-27 | 2016-12-20 | Transdermal drug delivery method and system |
US16/933,836 US20210169822A1 (en) | 2003-10-27 | 2020-07-20 | Transdermal drug delivery method and system |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH01833/03 | 2003-10-27 | ||
CH1833/03 | 2003-10-27 | ||
CH18332003 | 2003-10-27 | ||
PCT/IB2004/002947 WO2005039685A1 (en) | 2003-10-27 | 2004-09-13 | Transdermal drug delivery method and system |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2004/002947 Continuation WO2005039685A1 (en) | 2003-10-27 | 2004-09-13 | Transdermal drug delivery method and system |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/892,006 Division US8673346B2 (en) | 2003-10-27 | 2013-05-10 | Transdermal drug delivery method and system |
Publications (2)
Publication Number | Publication Date |
---|---|
US20050238704A1 US20050238704A1 (en) | 2005-10-27 |
US8440221B2 true US8440221B2 (en) | 2013-05-14 |
Family
ID=34468800
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/711,389 Active 2027-08-24 US8440221B2 (en) | 2003-10-27 | 2004-09-15 | Transdermal drug delivery method and system |
US13/892,006 Active US8673346B2 (en) | 2003-10-27 | 2013-05-10 | Transdermal drug delivery method and system |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/892,006 Active US8673346B2 (en) | 2003-10-27 | 2013-05-10 | Transdermal drug delivery method and system |
Country Status (7)
Country | Link |
---|---|
US (2) | US8440221B2 (en) |
EP (1) | EP1682211B1 (en) |
AT (1) | ATE448828T1 (en) |
CA (1) | CA2544291C (en) |
DE (1) | DE602004024228D1 (en) |
ES (1) | ES2336214T3 (en) |
WO (1) | WO2005039685A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46217E1 (en) | 2005-05-24 | 2016-11-29 | Chrono Therapeutics Inc. | Portable drug delivery device including a detachable and replaceable administration or dosing element |
US9555227B2 (en) | 2004-09-13 | 2017-01-31 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery |
US9669199B2 (en) | 2004-09-13 | 2017-06-06 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
US20200101241A1 (en) * | 2014-03-19 | 2020-04-02 | Vaporox, Inc. | Portable medical treatment system and method of use |
US10653686B2 (en) | 2011-07-06 | 2020-05-19 | Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8734339B2 (en) * | 1996-12-16 | 2014-05-27 | Ip Holdings, Inc. | Electronic skin patch for real time monitoring of cardiac activity and personal health management |
CA2544291C (en) | 2003-10-27 | 2013-01-08 | University Of Basel | Transdermal drug delivery method and system |
US20070042026A1 (en) * | 2005-03-17 | 2007-02-22 | Wille John J | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions |
ES2527340T3 (en) * | 2005-05-24 | 2015-01-22 | Chrono Therapeutics, Inc. | Portable drug delivery device that includes a removable and replaceable dosage or administration element |
US20080156821A1 (en) * | 2006-04-25 | 2008-07-03 | Bradley Stuart Galer | Topical preparation dispensers and methods of using the same |
US20070248656A1 (en) * | 2006-04-25 | 2007-10-25 | Galer Bradley S | Topical preparation dispensers and methods of using the same |
US8642093B2 (en) | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
US20090112197A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc | Devices configured to facilitate release of nitric oxide |
KR100800324B1 (en) | 2007-02-07 | 2008-02-01 | 아메스산업(주) | Method of transferring sample using multi air gap |
CA2702000C (en) * | 2007-10-09 | 2017-03-28 | Universite Rene Descartes - Paris V | Device for administering cells and cell-therapy methods using said device |
US10080823B2 (en) * | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
US8877508B2 (en) | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US20110182970A1 (en) * | 2007-10-30 | 2011-07-28 | Hyde Roderick A | Nitric oxide sensors and systems |
JP2011525916A (en) * | 2008-06-25 | 2011-09-29 | エフイー3 メディカル, インコーポレイテッド | Patches and methods for transdermal delivery of therapeutically effective amounts of iron |
US9008765B2 (en) | 2009-02-12 | 2015-04-14 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings |
WO2010093472A2 (en) * | 2009-02-12 | 2010-08-19 | Incube Labs, Llc | Method and apparatus for oscillatory iontophoretic transdermal delivery of a therapeutic agent |
US8190252B2 (en) * | 2009-02-12 | 2012-05-29 | Incube Labs, Llc | Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes |
US8961492B2 (en) | 2009-02-12 | 2015-02-24 | Incube Labs, Llc | System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation |
US8821945B2 (en) * | 2009-04-25 | 2014-09-02 | Fe3 Medical, Inc. | Method for transdermal iontophoretic delivery of chelated agents |
US8417330B2 (en) * | 2009-06-26 | 2013-04-09 | Incube Labs, Llc | Corrosion resistant electrodes for iontophoretic transdermal delivery devices and methods of use |
US8903485B2 (en) * | 2009-08-06 | 2014-12-02 | Incube Labs, Llc | Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes |
US8685038B2 (en) | 2009-12-07 | 2014-04-01 | Incube Labs, Llc | Iontophoretic apparatus and method for marking of the skin |
WO2011100376A2 (en) | 2010-02-10 | 2011-08-18 | Incube Labs, Llc | Methods and architecture for power optimization of iontophoretic transdermal drug delivery |
EA032537B1 (en) | 2010-06-07 | 2019-06-28 | Эмджен Инк. | Method of operation of a drug delivery device |
EP3626304A1 (en) | 2011-03-24 | 2020-03-25 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents |
US11583633B2 (en) | 2018-04-03 | 2023-02-21 | Amgen Inc. | Systems and methods for delayed drug delivery |
JP7377818B2 (en) * | 2018-05-01 | 2023-11-10 | シーエスピー テクノロジーズ,インコーポレイティド | Drug delivery devices and methods of using and making drug delivery devices |
WO2021021667A1 (en) * | 2019-07-26 | 2021-02-04 | Ryah Medtech, Inc. | Electronic patch for transdermal delivery of medical compositions |
WO2022261094A1 (en) * | 2021-06-08 | 2022-12-15 | W. L. Gore & Associates, Inc. | Treatment media delivery device and methods for targeted delivery thereof |
Citations (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4545990A (en) | 1982-11-22 | 1985-10-08 | L'oreal | Anti-acne composition |
US4708716A (en) | 1983-08-18 | 1987-11-24 | Drug Delivery Systems Inc. | Transdermal drug applicator |
US4917895A (en) | 1987-11-02 | 1990-04-17 | Alza Corporation | Transdermal drug delivery device |
JPH02202813A (en) | 1989-01-31 | 1990-08-10 | Sekisui Chem Co Ltd | Percutaneous absorbing preparation |
US5242941A (en) | 1990-12-04 | 1993-09-07 | State Of Oregon | Methods of treating circadian rhythm disorders |
US5273756A (en) | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset |
CA2142871A1 (en) | 1992-08-25 | 1994-03-03 | Jesus Miranda | Printed transdermal drug delivery device |
US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
US5370635A (en) | 1992-02-04 | 1994-12-06 | Asulab S.A. | Device for delivering a medicament |
US5389679A (en) | 1992-01-21 | 1995-02-14 | Alliger; Howard | Method of treating small mouth ulcers with lactic acid |
US5405614A (en) | 1992-04-08 | 1995-04-11 | International Medical Associates, Inc. | Electronic transdermal drug delivery system |
US5505958A (en) | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
US5538503A (en) * | 1993-09-15 | 1996-07-23 | Henley; Julian L. | Programmable apparatus for reducing substance dependency in transdermal drug delivery |
US5616332A (en) | 1993-07-23 | 1997-04-01 | Herstein; Morris | Cosmetic skin-renewal-stimulating composition with long-term irritation control |
US5785688A (en) | 1996-05-07 | 1998-07-28 | Ceramatec, Inc. | Fluid delivery apparatus and method |
US5879322A (en) | 1995-03-24 | 1999-03-09 | Alza Corporation | Self-contained transdermal drug delivery device |
US5932240A (en) | 1992-04-08 | 1999-08-03 | Americare Technology, Inc. | Multidose transdermal drug delivery system |
US5993435A (en) * | 1990-04-30 | 1999-11-30 | Alza Corporation | Device and method of iontophoretic drug delivery |
US6068853A (en) | 1994-04-13 | 2000-05-30 | Novartis Corporation | Temporally controlled drug delivery systems |
US6129702A (en) | 1996-12-03 | 2000-10-10 | Fraunhofer-Gesellschaft Zur Forderung Angewandten Forschung E.V. | Medicament dosing system |
US6165155A (en) | 1997-02-07 | 2000-12-26 | Sarcos, Lc | Multipathway electronically-controlled drug delivery system |
US6211296B1 (en) * | 1998-11-05 | 2001-04-03 | The B. F. Goodrich Company | Hydrogels containing substances |
US6214379B1 (en) | 1998-04-02 | 2001-04-10 | Kv Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
US6374136B1 (en) * | 1997-12-22 | 2002-04-16 | Alza Corporation | Anhydrous drug reservoir for electrolytic transdermal delivery device |
US20020127256A1 (en) | 2001-03-01 | 2002-09-12 | Howard Murad | Compositions and methods for treating dermatological disorders |
WO2003022349A2 (en) | 2001-09-07 | 2003-03-20 | Highland Innovation Centre Limited | Ultrasound driven device for accelerated transfer of substances across porous boundaries |
US6539250B1 (en) | 1999-12-15 | 2003-03-25 | David S. Bettinger | Programmable transdermal therapeutic apparatus |
US20030065294A1 (en) * | 2001-09-28 | 2003-04-03 | Pickup Ray L. | Cutaneous administration system |
US6595956B1 (en) | 1998-03-23 | 2003-07-22 | Joseph Gross | Drug delivery device |
US6638528B1 (en) | 2000-01-20 | 2003-10-28 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
US6723086B2 (en) | 2001-05-07 | 2004-04-20 | Logiq Wireless Solutions, Inc. | Remote controlled transdermal medication delivery device |
US20040138074A1 (en) | 2002-05-01 | 2004-07-15 | Nawaz Ahmad | Warming and nonirritating lubricant compositions and method of comparing irritation |
US20050034842A1 (en) | 2003-08-11 | 2005-02-17 | David Huber | Electroosmotic micropumps with applications to fluid dispensing and field sampling |
US6861066B2 (en) | 2002-03-11 | 2005-03-01 | Health Plus International Inc. | Method for the delivery of a biologically active agent |
US6867342B2 (en) | 1998-06-18 | 2005-03-15 | 3M Innovative Properties Company | Drug delivery dressing having fluid control film |
US6887202B2 (en) | 2000-06-01 | 2005-05-03 | Science Applications International Corporation | Systems and methods for monitoring health and delivering drugs transdermally |
US20050238704A1 (en) | 2003-10-27 | 2005-10-27 | Werner Zumbrunn | Transdermal drug delivery method and system |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6068583A (en) * | 1999-04-15 | 2000-05-30 | Kimberly-Clark Worldwide, Inc. | Consumer-activated clip lift feature for tissue cartons |
DE19958554C2 (en) * | 1999-07-02 | 2002-06-13 | Lohmann Therapie Syst Lts | Microreservoir system based on polysiloxanes and ambiphilic solvents and their manufacture |
WO2006127905A2 (en) | 2005-05-24 | 2006-11-30 | Chrono Therapeutics, Inc. | Portable drug delivery device |
-
2004
- 2004-09-13 CA CA2544291A patent/CA2544291C/en active Active
- 2004-09-13 EP EP04787507A patent/EP1682211B1/en active Active
- 2004-09-13 WO PCT/IB2004/002947 patent/WO2005039685A1/en active Application Filing
- 2004-09-13 AT AT04787507T patent/ATE448828T1/en not_active IP Right Cessation
- 2004-09-13 DE DE602004024228T patent/DE602004024228D1/en active Active
- 2004-09-13 ES ES04787507T patent/ES2336214T3/en active Active
- 2004-09-15 US US10/711,389 patent/US8440221B2/en active Active
-
2013
- 2013-05-10 US US13/892,006 patent/US8673346B2/en active Active
Patent Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4545990A (en) | 1982-11-22 | 1985-10-08 | L'oreal | Anti-acne composition |
US4708716A (en) | 1983-08-18 | 1987-11-24 | Drug Delivery Systems Inc. | Transdermal drug applicator |
US4917895A (en) | 1987-11-02 | 1990-04-17 | Alza Corporation | Transdermal drug delivery device |
JPH02202813A (en) | 1989-01-31 | 1990-08-10 | Sekisui Chem Co Ltd | Percutaneous absorbing preparation |
US5993435A (en) * | 1990-04-30 | 1999-11-30 | Alza Corporation | Device and method of iontophoretic drug delivery |
US5242941A (en) | 1990-12-04 | 1993-09-07 | State Of Oregon | Methods of treating circadian rhythm disorders |
US5273756A (en) | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset |
US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
US5820875A (en) | 1991-10-10 | 1998-10-13 | Cygnus, Inc. | Device for administering drug transdermally with a controlled temporal change in skin flux |
US5389679A (en) | 1992-01-21 | 1995-02-14 | Alliger; Howard | Method of treating small mouth ulcers with lactic acid |
US5370635A (en) | 1992-02-04 | 1994-12-06 | Asulab S.A. | Device for delivering a medicament |
US5405614A (en) | 1992-04-08 | 1995-04-11 | International Medical Associates, Inc. | Electronic transdermal drug delivery system |
US5932240A (en) | 1992-04-08 | 1999-08-03 | Americare Technology, Inc. | Multidose transdermal drug delivery system |
CA2142871A1 (en) | 1992-08-25 | 1994-03-03 | Jesus Miranda | Printed transdermal drug delivery device |
US5616332A (en) | 1993-07-23 | 1997-04-01 | Herstein; Morris | Cosmetic skin-renewal-stimulating composition with long-term irritation control |
US5538503A (en) * | 1993-09-15 | 1996-07-23 | Henley; Julian L. | Programmable apparatus for reducing substance dependency in transdermal drug delivery |
US6068853A (en) | 1994-04-13 | 2000-05-30 | Novartis Corporation | Temporally controlled drug delivery systems |
US5505958A (en) | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
US5879322A (en) | 1995-03-24 | 1999-03-09 | Alza Corporation | Self-contained transdermal drug delivery device |
US5785688A (en) | 1996-05-07 | 1998-07-28 | Ceramatec, Inc. | Fluid delivery apparatus and method |
US6129702A (en) | 1996-12-03 | 2000-10-10 | Fraunhofer-Gesellschaft Zur Forderung Angewandten Forschung E.V. | Medicament dosing system |
US6165155A (en) | 1997-02-07 | 2000-12-26 | Sarcos, Lc | Multipathway electronically-controlled drug delivery system |
US6374136B1 (en) * | 1997-12-22 | 2002-04-16 | Alza Corporation | Anhydrous drug reservoir for electrolytic transdermal delivery device |
US6595956B1 (en) | 1998-03-23 | 2003-07-22 | Joseph Gross | Drug delivery device |
US6214379B1 (en) | 1998-04-02 | 2001-04-10 | Kv Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
US6867342B2 (en) | 1998-06-18 | 2005-03-15 | 3M Innovative Properties Company | Drug delivery dressing having fluid control film |
US6211296B1 (en) * | 1998-11-05 | 2001-04-03 | The B. F. Goodrich Company | Hydrogels containing substances |
US6539250B1 (en) | 1999-12-15 | 2003-03-25 | David S. Bettinger | Programmable transdermal therapeutic apparatus |
US6638528B1 (en) | 2000-01-20 | 2003-10-28 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
US6887202B2 (en) | 2000-06-01 | 2005-05-03 | Science Applications International Corporation | Systems and methods for monitoring health and delivering drugs transdermally |
US20050182307A1 (en) | 2000-06-01 | 2005-08-18 | Science Applications International Corporation | Systems and methods for monitoring health and delivering drugs transdermally |
US20020127256A1 (en) | 2001-03-01 | 2002-09-12 | Howard Murad | Compositions and methods for treating dermatological disorders |
US6723086B2 (en) | 2001-05-07 | 2004-04-20 | Logiq Wireless Solutions, Inc. | Remote controlled transdermal medication delivery device |
WO2003022349A2 (en) | 2001-09-07 | 2003-03-20 | Highland Innovation Centre Limited | Ultrasound driven device for accelerated transfer of substances across porous boundaries |
US20030065294A1 (en) * | 2001-09-28 | 2003-04-03 | Pickup Ray L. | Cutaneous administration system |
US6723077B2 (en) | 2001-09-28 | 2004-04-20 | Hewlett-Packard Development Company, L.P. | Cutaneous administration system |
US6861066B2 (en) | 2002-03-11 | 2005-03-01 | Health Plus International Inc. | Method for the delivery of a biologically active agent |
US20040138074A1 (en) | 2002-05-01 | 2004-07-15 | Nawaz Ahmad | Warming and nonirritating lubricant compositions and method of comparing irritation |
US20050034842A1 (en) | 2003-08-11 | 2005-02-17 | David Huber | Electroosmotic micropumps with applications to fluid dispensing and field sampling |
US20050238704A1 (en) | 2003-10-27 | 2005-10-27 | Werner Zumbrunn | Transdermal drug delivery method and system |
Non-Patent Citations (24)
Title |
---|
Benzoyl Peroxide: "Enhancing Antibiotic Efficacy in Acne Management," http://www.skintherapyletter.com/2010/15.10/2.html, Nov. 2010, pp. 1-8, Accessed May 18, 2011. |
International Preliminary Report on Patentability; PCT/IB2004/002947; May 1, 2006. |
L. Molander et al., "Reduction of Tobacco Withdrawl Symptons with a Sublingual Nicotine Tablet: A Placebo Controlled Study," Nicotine & Tob. Res., 2000, 2, pp. 187-191. |
Notice of Allowance cited in related U.S. Appl. No. 11/162,525, dated Apr. 26, 2010. |
Notice of Allowance cited in related U.S. Appl. No. 11/981,672, dated Mar. 2, 2012. |
Office Action cited in related U.S. Appl. No. 11/083,178, dated Jan. 26, 2012. |
Office Action cited in related U.S. Appl. No. 11/083,178, dated May 27, 2011. |
Office Action cited in related U.S. Appl. No. 11/162,517, dated Nov. 19, 2012. |
Office Action cited in related U.S. Appl. No. 11/162,517, dated Nov. 24, 2009. |
Office Action cited in related U.S. Appl. No. 11/162,525, dated Feb. 5, 2010. |
Office Action cited in related U.S. Appl. No. 11/981,672, dated Apr. 4, 2011. |
Office Action cited in related U.S. Appl. No. 11/981,672, dated Nov. 10, 2011. |
Office Action cited in related U.S. Appl. No. 12/835,693, dated Aug. 1, 2012. |
Office Action cited in related U.S. Appl. No. 12/835,693, dated Dec. 20, 2012. |
Office Action for related U.S. Appl. No. 10/711,389 dated Jul. 1, 2009. |
Office Action for related U.S. Appl. No. 11/083,178 dated Oct. 2, 2009. |
Office Action for related U.S. Appl. No. 11/162,525 dated Aug. 27, 2009. |
Office Action for related U.S. Appl. No. 11/162,525 dated Feb. 19, 2009. |
Office Action for related U.S. Appl. No. 11/981,672 dated Oct. 7, 2009. |
Prosise et al., (Effect of abstinence from smoking on sleep and day time sleepiness), Amer. College of Chest Physicians, vol. 105, pp. 1136-1141 (1994). |
Shin et al., Enhanced Bioavailability of Triprolidine from the Transdermal TPX Matrix System in Rabbits, Intern. Journ. of Pharm., 234, pp. 67-73 (2002). |
The Science and Practice of Pharmacy, 19th Ed., p. 1582-1584, (1995). |
U.S. Office Action cited in related U.S. Appl. No. 11/162,517, dated Jun. 3, 2010. |
U.S. Office Action cited in related U.S. Appl. No. 11/981,672, dated Mar. 23, 2009. |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9555226B2 (en) | 2003-10-27 | 2017-01-31 | Chrono Therapeutics Inc. | Transdermal drug delivery method and system |
US10716764B2 (en) | 2003-10-27 | 2020-07-21 | Morningside Venture Investments Limited | Transdermal drug delivery method and system |
US10258778B2 (en) | 2004-09-13 | 2019-04-16 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US11471424B2 (en) | 2004-09-13 | 2022-10-18 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
US9555227B2 (en) | 2004-09-13 | 2017-01-31 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery |
US10258738B2 (en) | 2004-09-13 | 2019-04-16 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US9669199B2 (en) | 2004-09-13 | 2017-06-06 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
USRE46217E1 (en) | 2005-05-24 | 2016-11-29 | Chrono Therapeutics Inc. | Portable drug delivery device including a detachable and replaceable administration or dosing element |
US10653686B2 (en) | 2011-07-06 | 2020-05-19 | Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
US20200101241A1 (en) * | 2014-03-19 | 2020-04-02 | Vaporox, Inc. | Portable medical treatment system and method of use |
US11744961B2 (en) * | 2014-03-19 | 2023-09-05 | Vaporox, Inc. | Portable medical treatment system and method of use |
US10232156B2 (en) | 2015-01-28 | 2019-03-19 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
US11400266B2 (en) | 2015-01-28 | 2022-08-02 | Morningside Venture Investments Limited | Drug delivery methods and systems |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
Also Published As
Publication number | Publication date |
---|---|
ATE448828T1 (en) | 2009-12-15 |
CA2544291C (en) | 2013-01-08 |
EP1682211B1 (en) | 2009-11-18 |
EP1682211A1 (en) | 2006-07-26 |
DE602004024228D1 (en) | 2009-12-31 |
US20130338645A1 (en) | 2013-12-19 |
US8673346B2 (en) | 2014-03-18 |
CA2544291A1 (en) | 2005-05-06 |
WO2005039685A1 (en) | 2005-05-06 |
ES2336214T3 (en) | 2010-04-09 |
US20050238704A1 (en) | 2005-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210169822A1 (en) | Transdermal drug delivery method and system | |
US8673346B2 (en) | Transdermal drug delivery method and system | |
USRE46217E1 (en) | Portable drug delivery device including a detachable and replaceable administration or dosing element | |
CA2552690C (en) | Transdermal delivery using encapsulated agent activated by ultrasound and/or heat | |
US6623457B1 (en) | Method and apparatus for the transdermal administration of a substance | |
EP1992386B1 (en) | Transdermal drug administration apparatus having microneedles | |
JPH03151982A (en) | Method and device for percutaneous administration of protain and peptide drug | |
CN1079916A (en) | By activated iontophoresis apparatus of user and using method thereof | |
JP4072268B2 (en) | Skin absorption type chemical solution administration device | |
CA2609351C (en) | Portable drug delivery device | |
Ibhrahimpatnam et al. | TRANSDERMAL DRUG DELIVERY SYSTEMS | |
JP2008055197A (en) | Method of discharge and liquid composition for discharge |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CHRONO THERAPEUTICS, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IMANIDIS, GEORGE;DIPIERRO, GUY;SIGNING DATES FROM 20051013 TO 20060110;REEL/FRAME:017178/0266 Owner name: CHRONO THERAPEUTICS, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IMANIDIS, GEORGE;DIPIERRO, GUY;REEL/FRAME:017178/0266;SIGNING DATES FROM 20051013 TO 20060110 |
|
AS | Assignment |
Owner name: FACHHOCHSCHULE SOLOTHURN, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VAN DE VENN, HANS WERNER;REEL/FRAME:019604/0184 Effective date: 20050415 Owner name: FACHHOCHSCHULE SOLOTHURN, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZUMBRUNN, WERNER;REEL/FRAME:019604/0688 Effective date: 20050422 |
|
AS | Assignment |
Owner name: CHRONO THERAPEUTICS, INC, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY OF BASEL AND THE UNIVERSITY OF APPLIED SCIENCE NORTHWESTERN SWITZERLAND AKA FHSO AND FACHHOCHSCHULE SOLOTHURN;REEL/FRAME:029719/0761 Effective date: 20120312 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |
|
AS | Assignment |
Owner name: MORNINGSIDE VENTURE INVESTMENTS LIMITED, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CTI (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC;REEL/FRAME:055382/0388 Effective date: 20200408 Owner name: CTI (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHRONO THERAPEUTICS, INC.;REEL/FRAME:055384/0227 Effective date: 20191021 |